Gemcitabine has been noted as the first line of defense for pancreatic cancer, but its efficacy is being decreased by the chemoresistance caused by NF-κB, which prevents improvements in survival rates and prognosis. This evidence concerns the gene NFKB1 and pancreatic neoplasm.